Brainstorm Capital Expenditures vs Free Cash Flow Analysis
| BCLI Stock | USD 1.74 0.12 7.41% |
Brainstorm Cell financial indicator trend analysis is way more than just evaluating Brainstorm Cell Ther prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Brainstorm Cell Ther is a good investment. Please check the relationship between Brainstorm Cell Capital Expenditures and its Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Capital Expenditures vs Free Cash Flow
Capital Expenditures vs Free Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Brainstorm Cell Ther Capital Expenditures account and Free Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Brainstorm Cell's Capital Expenditures and Free Cash Flow is -0.64. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Brainstorm Cell Therapeutics, assuming nothing else is changed. The correlation between historical values of Brainstorm Cell's Capital Expenditures and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Brainstorm Cell Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Capital Expenditures i.e., Brainstorm Cell's Capital Expenditures and Free Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.64 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Capital Expenditures
Capital Expenditures are funds used by Brainstorm Cell Ther to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Brainstorm Cell operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Most indicators from Brainstorm Cell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Brainstorm Cell Ther current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. The Brainstorm Cell's current Selling General Administrative is estimated to increase to about 11.2 M, while Issuance Of Capital Stock is projected to decrease to under 13.7 M.
Brainstorm Cell fundamental ratios Correlations
Click cells to compare fundamentals
Brainstorm Cell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Brainstorm Cell fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 6.5M | 51.3M | 29.3M | 8.5M | 4.2M | 4.0M | |
| Other Current Liab | 1M | 506K | 1.2M | 1.1M | 2.8M | 3.0M | |
| Total Current Liabilities | 17.7M | 11.2M | 6.3M | 8.8M | 7.8M | 4.2M | |
| Total Stockholder Equity | (12.2M) | 35.5M | 19.3M | (3.0M) | (4.9M) | (4.6M) | |
| Net Debt | 1.8M | (30.6M) | (13.8M) | 3.3M | (628K) | (659.4K) | |
| Retained Earnings | (117.3M) | (149.1M) | (173.5M) | (197.8M) | (215.0M) | (204.3M) | |
| Cash | 536K | 37.8M | 18.9M | 772K | 1.3M | 1.2M | |
| Non Current Assets Total | 3.2M | 8.0M | 6.0M | 5.3M | 2.3M | 1.6M | |
| Cash And Short Term Investments | 569K | 41.9M | 22.1M | 3.0M | 1.3M | 1.2M | |
| Common Stock Shares Outstanding | 21.9M | 29.8M | 36.2M | 36.5M | 43.1M | 45.2M | |
| Liabilities And Stockholders Equity | 6.5M | 51.3M | 29.3M | 8.5M | 4.2M | 4.0M | |
| Non Current Liabilities Total | 1.1M | 4.6M | 3.6M | 2.7M | 1.3M | 1.3M | |
| Other Current Assets | 1.2M | 432K | 984K | 1.1M | 548K | 306.8K | |
| Other Stockholder Equity | 105.0M | 184.5M | 192.9M | 194.8M | 210.1M | 220.6M | |
| Total Liab | 18.8M | 15.8M | 9.9M | 11.5M | 9.1M | 4.9M | |
| Total Current Assets | 3.4M | 43.2M | 23.3M | 3.1M | 1.9M | 1.8M | |
| Property Plant And Equipment Net | 3.1M | 8.0M | 6.0M | 5.3M | 2.1M | 1.6M | |
| Property Plant And Equipment Gross | 3.1M | 8.0M | 8.2M | 5.3M | 6.1M | 6.4M | |
| Accounts Payable | 15.4M | 5.4M | 3.7M | 6.2M | 5.0M | 2.7M | |
| Non Currrent Assets Other | 32.0K | 26.0K | 27.0K | 23.0K | 207K | 137.3K | |
| Net Receivables | 2.4M | 304K | 86K | 91K | 51K | 48.5K | |
| Other Assets | 32K | 26K | 27K | 23K | 26.5K | 25.1K | |
| Property Plant Equipment | 3.1M | 8.0M | 6.0M | 5.3M | 6.1M | 6.4M | |
| Net Tangible Assets | (12.2M) | 35.5M | 19.3M | (3.0M) | (3.5M) | (3.3M) | |
| Retained Earnings Total Equity | (94.0M) | (117.3M) | (149.1M) | (173.5M) | (156.2M) | (148.4M) | |
| Short Term Investments | 33K | 4.1M | 3.2M | 2.2M | 2.5M | 4.9M | |
| Capital Surpluse | 94.6M | 105.0M | 184.7M | 193.0M | 221.9M | 233.0M | |
| Net Invested Capital | (12.2M) | 35.5M | 19.3M | (3.0M) | (3.5M) | (3.3M) | |
| Net Working Capital | (14.3M) | 32.0M | 17.0M | (5.7M) | (6.5M) | (6.2M) |
Currently Active Assets on Macroaxis
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.45) | Return On Assets (1.78) | Return On Equity (11.22) |
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.